Noelia Fandos
R&d
Zaragoza, AR, Spain
Zaragoza, AR, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: May 27, 2026
Clinical validation of a plasma-based antibody-free LC-MS method for identifying CSF amyloid positivity in mild cognitive impairment.
Journal: Frontiers in aging neuroscience
Published: August 07, 2025
Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer's disease in individuals with subjective cognitive decline: 5-year follow-up of the FACEHBI cohort.
Journal: The journal of prevention of Alzheimer's disease
Published: June 12, 2025
Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: June 04, 2025
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
Journal: Alzheimer's research & therapy
Published: October 20, 2022
The global Alzheimer's Association round robin study on plasma amyloid β methods.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: June 24, 2021
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 23, 2021
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain.
Journal: Brain communications
Published: December 02, 2019
Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: August 07, 2019
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis.
Journal: Neurology
Published: January 09, 2019
Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old.
Journal: Frontiers in aging neuroscience
Published: July 30, 2018
Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: September 27, 2017
Last Updated: 09/26/2026